Selected research
Industry Research
Short Bowel Syndrome (SBS) Drugs Industry Research Report 2026
Market perspective
The global Short Bowel Syndrome (SBS) Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Short Bowel Syndrome (SBS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Short Bowel Syndrome (SBS) Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Short Bowel Syndrome (SBS) Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Short Bowel Syndrome (SBS) Drugs include Takeda, Merck, Zealand Pharma, Sancilio Pharmaceuticals, OxThera, Nutrinia, Naia Pharmaceuticals, Emmaus Medical and Ardelyx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Short Bowel Syndrome (SBS) Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Short Bowel Syndrome (SBS) Drugs Market by Company
Takeda
Merck
Zealand Pharma
Sancilio Pharmaceuticals
OxThera
Nutrinia
Naia Pharmaceuticals
Emmaus Medical
Ardelyx
Short Bowel Syndrome (SBS) Drugs Segment by Type
Glutamine
Growth Hormone
Glucagon-Like Peptide-2 (GLP-2)
Other
Short Bowel Syndrome (SBS) Drugs Segment by Application
Hospitals
Clinics
Retail Pharmacies
Short Bowel Syndrome (SBS) Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short Bowel Syndrome (SBS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Short Bowel Syndrome (SBS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short Bowel Syndrome (SBS) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Short Bowel Syndrome (SBS) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Short Bowel Syndrome (SBS) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Short Bowel Syndrome (SBS) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Glutamine
- Growth Hormone
- Glucagon-Like Peptide-2 (GLP-2)
- Other
Applications
- Hospitals
- Clinics
- Retail Pharmacies
Companies covered
- Takeda
- Merck
- Zealand Pharma
- Sancilio Pharmaceuticals
- OxThera
- Nutrinia
- Naia Pharmaceuticals
- Emmaus Medical
- Ardelyx
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Short Bowel Syndrome (SBS) Drugs Market Size (2021-2032)
- 2.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales (2021-2032)
- 2.2.3 Global Short Bowel Syndrome (SBS) Drugs Market Average Price (2021-2032)
- 2.3 Short Bowel Syndrome (SBS) Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Glutamine
- 2.3.3 Growth Hormone
- 2.3.4 Glucagon-Like Peptide-2 (GLP-2)
- 2.3.5 Other
- 2.4 Short Bowel Syndrome (SBS) Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Short Bowel Syndrome (SBS) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Short Bowel Syndrome (SBS) Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Short Bowel Syndrome (SBS) Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Short Bowel Syndrome (SBS) Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Short Bowel Syndrome (SBS) Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Short Bowel Syndrome (SBS) Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Short Bowel Syndrome (SBS) Drugs, Product Type & Application
- 3.8 Global Manufacturers of Short Bowel Syndrome (SBS) Drugs, Established Date
- 3.9 Global Short Bowel Syndrome (SBS) Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Zealand Pharma
- 4.3.1 Zealand Pharma Company Information
- 4.3.2 Zealand Pharma Business Overview
- 4.3.3 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Zealand Pharma Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.3.5 Zealand Pharma Recent Developments
- 4.4 Sancilio Pharmaceuticals
- 4.4.1 Sancilio Pharmaceuticals Company Information
- 4.4.2 Sancilio Pharmaceuticals Business Overview
- 4.4.3 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.4.5 Sancilio Pharmaceuticals Recent Developments
- 4.5 OxThera
- 4.5.1 OxThera Company Information
- 4.5.2 OxThera Business Overview
- 4.5.3 OxThera Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 OxThera Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.5.5 OxThera Recent Developments
- 4.6 Nutrinia
- 4.6.1 Nutrinia Company Information
- 4.6.2 Nutrinia Business Overview
- 4.6.3 Nutrinia Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Nutrinia Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.6.5 Nutrinia Recent Developments
- 4.7 Naia Pharmaceuticals
- 4.7.1 Naia Pharmaceuticals Company Information
- 4.7.2 Naia Pharmaceuticals Business Overview
- 4.7.3 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.7.5 Naia Pharmaceuticals Recent Developments
- 4.8 Emmaus Medical
- 4.8.1 Emmaus Medical Company Information
- 4.8.2 Emmaus Medical Business Overview
- 4.8.3 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Emmaus Medical Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.8.5 Emmaus Medical Recent Developments
- 4.9 Ardelyx
- 4.9.1 Ardelyx Company Information
- 4.9.2 Ardelyx Business Overview
- 4.9.3 Ardelyx Short Bowel Syndrome (SBS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ardelyx Short Bowel Syndrome (SBS) Drugs Product Portfolio
- 4.9.5 Ardelyx Recent Developments
5 Global Short Bowel Syndrome (SBS) Drugs Market Scenario by Region
- 5.1 Global Short Bowel Syndrome (SBS) Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021-2032
- 5.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2021-2026
- 5.2.2 Global Short Bowel Syndrome (SBS) Drugs Sales by Region: 2027-2032
- 5.3 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Region: 2027-2032
- 5.4 North America Short Bowel Syndrome (SBS) Drugs Market Facts & Figures by Country
- 5.4.1 North America Short Bowel Syndrome (SBS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 5.4.3 North America Short Bowel Syndrome (SBS) Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Short Bowel Syndrome (SBS) Drugs Market Facts & Figures by Country
- 5.5.1 Europe Short Bowel Syndrome (SBS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Short Bowel Syndrome (SBS) Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Short Bowel Syndrome (SBS) Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Short Bowel Syndrome (SBS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Short Bowel Syndrome (SBS) Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Short Bowel Syndrome (SBS) Drugs Market Facts & Figures by Country
- 5.7.1 South America Short Bowel Syndrome (SBS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 5.7.3 South America Short Bowel Syndrome (SBS) Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Short Bowel Syndrome (SBS) Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Short Bowel Syndrome (SBS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Short Bowel Syndrome (SBS) Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Short Bowel Syndrome (SBS) Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021-2032)
- 6.1.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Short Bowel Syndrome (SBS) Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021-2032)
- 7.1.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Short Bowel Syndrome (SBS) Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Short Bowel Syndrome (SBS) Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Short Bowel Syndrome (SBS) Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Short Bowel Syndrome (SBS) Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Short Bowel Syndrome (SBS) Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Short Bowel Syndrome (SBS) Drugs Value Chain Analysis
- 8.1.1 Short Bowel Syndrome (SBS) Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Short Bowel Syndrome (SBS) Drugs Production Mode & Process
- 8.2 Short Bowel Syndrome (SBS) Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Short Bowel Syndrome (SBS) Drugs Distributors
- 8.2.3 Short Bowel Syndrome (SBS) Drugs Customers
9 Global Short Bowel Syndrome (SBS) Drugs Analyzing Market Dynamics
- 9.1 Short Bowel Syndrome (SBS) Drugs Industry Trends
- 9.2 Short Bowel Syndrome (SBS) Drugs Industry Drivers
- 9.3 Short Bowel Syndrome (SBS) Drugs Industry Opportunities and Challenges
- 9.4 Short Bowel Syndrome (SBS) Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst